---
title: "phoenix"
slug: "phoenix"
date: "2024-05-07"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[double_hit_and_double_expressors_in_lymphoma]]

# phoenix

ðŸ”¥ðŸª½

| Metric               | Ibrutinib + R-CHOP | Placebo + R-CHOP |
| -------------------- | ------------------ | ---------------- |
| Patients (N)         | 419                | 419              |
| Median Age (years)   | 62.0               | 62.0             |
| ABC Subtype (%)      | 75.9%              | 75.9%            |
| EFS (HR)\*\*         | 0.934              | -                |
| ABC Subtype EFS (HR) | 0.949              | -                |

**Subgroup Analysis (Age)**

| Metric                               | Ibrutinib + R-CHOP | Placebo + R-CHOP |
| ------------------------------------ | ------------------ | ---------------- |
| **Age < 60: EFS (HR)**               | 0.579              | -                |
| **Age < 60: PFS (HR)**               | 0.556              | -                |
| **Age < 60: OS (HR)**                | 0.330              | -                |
| **Age < 60: Serious Adverse Events** | 35.7%              | 28.6%            |
| **Age < 60: â‰¥ 6 R-CHOP Cycles (%)**  | 92.9%              | 93.0%            |
| **Age â‰¥ 60: EFS (HR)**               | Worse              | -                |
| **Age â‰¥ 60: PFS (HR)**               | Worse              | -                |
| **Age â‰¥ 60: OS (HR)**                | Worse              | -                |
| **Age â‰¥ 60: Serious Adverse Events** | 63.4%              | 38.2%            |
| **Age â‰¥ 60: â‰¥ 6 R-CHOP Cycles (%)**  | 73.7%              | 88.8%            |

**Main Takeaways:**

- Ibrutinib + R-CHOP didn't improve outcomes in the overall DLBCL population.
- **Crucially:** Ibrutinib + R-CHOP significantly benefited younger patients (< 60 years old).
- Ibrutinib + R-CHOP worsened outcomes and increased side effects in older patients (â‰¥ 60 years old).
